124 related articles for article (PubMed ID: 22587686)
21. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
22. The genetic determinants of atorvastatin response.
Rodrigues AC; Hirata MH; Hirata RD
Curr Opin Mol Ther; 2007 Dec; 9(6):545-53. PubMed ID: 18041665
[TBL] [Abstract][Full Text] [Related]
23. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
24. The effects of simvastatin on the pharmacokinectics of sitagliptin.
Cerra M; Luo WL; Li SX; Matthews C; O'Neill EA; Wagner JA; Stoch SA; Anderson MS
J Popul Ther Clin Pharmacol; 2012; 19(3):e356-60. PubMed ID: 23077137
[TBL] [Abstract][Full Text] [Related]
25. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR
J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470
[TBL] [Abstract][Full Text] [Related]
26. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
27. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
28. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Filippatos TD; Athyros VG; Elisaf MS
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):787-812. PubMed ID: 24746233
[TBL] [Abstract][Full Text] [Related]
30. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
31. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
[TBL] [Abstract][Full Text] [Related]
32. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
[TBL] [Abstract][Full Text] [Related]
33. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Athyros VG; Tziomalos K; Kakafika AI; Koumaras H; Karagiannis A; Mikhailidis DP
Am J Cardiol; 2008 Feb; 101(4):483-5. PubMed ID: 18312762
[TBL] [Abstract][Full Text] [Related]
35. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
[TBL] [Abstract][Full Text] [Related]
36. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
37. Sitagliptin: a review.
Subbarayan S; Kipnes M
Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
[TBL] [Abstract][Full Text] [Related]
38. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
40. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
